Abstract Number: 97 • Pediatric Rheumatology Symposium 2017
Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) with psychosis is challenging to treat with refractory cases often requiring prolonged hospitalization due to significant functional impairment and…Abstract Number: 2782 • ACR/ARHP Annual Meeting 2016
Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems
Background/Purpose: Lupus nephritis (LN) is one of the main causes of morbidity and mortality in SLE. Although a combination therapy using steroids and immunosuppressant…Abstract Number: 1812 • ACR/ARHP Annual Meeting 2015
The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease characterized by production and deposition of anti-dsDNA antibody. In recent years, treatment methods targeting antibody-producing B cell…
